Aptorum Group, a biopharmaceutical business, received a patent from the United States Patent and Trademark Office for their rapid pathogen infectious disease liquid biopsy diagnostics (RPIDD) technology on April 25, 2022.
According to the business, the patent provides deoxyribonucleic acid (DNA) library preparation for the RPIDD technology from samples containing many types of nucleic acids. Aptorum has an exclusive licensing arrangement with A*Star, a Singapore-based company that created the RPIDD technology.
About Aptorum Group
Aptorum Group Limited is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases.
About the RPIDD Test
RPIDD is a rapid pathogen molecular diagnostics method based on liquid biopsy.
Using next-generation sequencing (NGS) platforms and artificial intelligence (AI)-based software, new technologies are being developed to enrich pathogenic DNA/ribonucleic acid (RNA) for analysis. The analysis will be used to quickly identify and detect any foreign pathogens (virus, bacteria, fungus, parasites) in the DNA sample through their genome.
RPIDD technology has successfully detected pathogens ranging from bacteria and fungus to viruses in an unbiased manner and has been validated for human samples.
The RPIDD invention uses a novel method for preparing DNA libraries from samples containing multiple nucleic acid types. The nucleic acids are in relatively small amounts compared to non-nucleic acid molecules. They require a shorter turnaround time and significantly fewer steps to provide results than conventional DNA library preparation methods.
Nucleic acid contains information-carrying molecules developed naturally by the body.
A DNA library consists of DNA fragments cloned into vectors so that scientists can separate and examine the fragments of DNA that interest them.
A quick molecular liquid biopsy-based diagnostics strategy for infectious diseases will disrupt present procedures and, as a result, may lower the mortality and morbidity of infected patients in the long run.
Conventional first-line clinical diagnostics for infectious diseases, such as blood culture and polymerase chain reaction (PCR), will be revolutionized by the patented RPIDD approach.
Using Novel Methods for Infectious Disease Diagnostics
Infectious disease diagnostics is the process of identifying and characterizing the causal agents of infectious diseases. Infectious disease diagnosis can be based primarily on clinical signs and symptoms or on more rigorous diagnostic techniques such as infectious agent culturing, microscopy, biochemical screens, and genetic approaches.
The diagnosis of infectious disease present on a gene has been improved by applying the emerging next-generation sequencing methods, which was difficult to access with earlier applied Sanger sequencing methods. Significant advances in sequencing technologies and computational tools have enabled a growing number of genomic studies, resulting in massive volumes of patients’ data being generated. The data created by genomic projects and efforts necessitates in-depth analysis to derive potential insights that can subsequently be used to improve therapeutic outcomes.
The Europe infectious disease diagnostics market was worth $1.39billion in 2020 and is predicted to grow to $7.90billion by 2031, with a CAGR of 16.48% between 2021 and 2031.
Biotechnology businesses are heavily spending on research and development (R&D) to build their respective bioinformatics pipelines for research and clinical applications to meet this urgent need for downstream genetic data processing.
By detecting and analyzing proteins and nucleic acid sequences, infectious disease diagnostics promotes a fast-evolving variety of tests and systems that facilitate pathogen identification, viral load estimation, antibiotic and antiviral therapy selection, and other infectious disorders. Infectious illness diagnostics also provides prognostic assessments for various diseases and treatment selection and drug treatment efficacy monitoring.
Conclusion
The MedTech industry has been working on ways to effectively diagnose infectious diseases since the emergence of coronavirus. The results witnessed by the industry are revolutionizing. The novel methods can be used to detect COVID-19 and also other similar viruses. The biotechnology business has gained traction due to the development of tests such as RPIDD.
